Replies to post #488351 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

biosectinvestor, we can have a valid discussion if you would answer any of my questions. First, this statement is patently false and it does not make any sense:

You believe that deducted Improvements to the leased facility would be meaningfully transferred, at this stage without an actual commercialization plan that still requires NWBO to fund it and that somehow they would earn $50-100 million. That makes no sense.

This is what I actually said:

Of course, NWBio should and would only do this transaction if they had a firm agreement with Cognate / CRL to use their CDMO services for the worldwide production of DCVax-L and DCVax Direct.

I will agree to disagree biosectinvestor. The primary reason why the Sawston facility is not built-up now, is because that is a capital-intensive endeavor. NWBio can not afford to do that now. It will cost over $100 million to build out the entire 88,000 SF facility.

I don’t think NWBio wants to manufacture DCVax directly. I would rather NWBio not invest that much of its own money to build out CDMO facilities. I rather NWBio focus its resources on expanding approved label indications for DCVax-L and DCVax Direct for all or most solid tumor cancers worldwide.

I prefer to leave the manufacturing of the DCVax vaccine platform to a CDMO (CRL) that has a global footprint and the capital resources to build out the Sawston facility, and expand facilities worldwide.

Let me know when you would like to answer my questions and have a real discussion about these issues. Until then, I will agree to disagree with you.